<DOC>
	<DOCNO>NCT02974322</DOCNO>
	<brief_summary>The purpose study test effect experimental medication GED-0301 ( mongersen ) evaluate safety patient ( ≥ 12 year age ) active Crohn 's disease . The study test GED-0301 compare placebo 12 week . The study treatment blind mean patient study doctor know treatment assign . Patients study allow treatment stable dose oral aminosalicylates , oral corticosteroid , immunosupressants antibiotics treatment Crohn 's disease . Adolescent patient also allow treatment stable dos exclusive enteral nutrition growth hormone . All patient complete study option enter long term active treatment study .</brief_summary>
	<brief_title>A Study Efficacy Safety Mongersen ( GED-0301 ) Treatment Adult Adolescent Subjects With Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : Male female ≥ 12 year Subject able swallow IP tablet Active Crohn 's disease ( CD ) disease determine Crohn 's Disease Activity Index ( CDAI ) score Simple Endoscopic Score Crohn 's Disease ( SESCD ) Must meet determine average minimum number daily stool rating abdominal pain 7day period Subject must fail experienced intolerance least one following : budesonide ; systemic corticosteroid ; immunosuppressant ( eg , azathiopurine , 6mercaptopurine , methotrexate ) ; biologics treatment CD ( ie , infliximab , adalimumab , certolizumab , vedolizumab ) . • The presence follow exclude subject enrollment : Diagnosis ulcerative colitis ( UC ) , indeterminate colitis , ischemic colitis , microscopic colitis , radiation colitis diverticular diseaseassociated colitis , colitis due immunodeficiency Local manifestation Crohn 's Disease ( CD ) abscesses , short bowel syndrome ; disease complication surgery might indicate could confound evaluation efficacy Subject strictures prestenotic dilatation , require procedural intervention , obstructive symptom . In addition , subject colonic stricture passable ageappropriate colonoscope , strictures ileum ileocecal valve fibrotic nature , exclude Intestinal resection within 6 month intraabdominal surgery within 3 month prior Screening Visit Ileostomy colostomy Subject history clinically significant medical condition , investigator 's opinion , would prevent subject participate study Adolescents delay growth pubertal development corticosteroid baseline continue treatment dose corticosteroid Week 12 visit .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>GED-0301</keyword>
	<keyword>Mongersen</keyword>
	<keyword>Adolescent</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Children</keyword>
</DOC>